419 Combined anti-VEGF, anti-CTLA4 and anti-PDL1 treatment induces strong immune responses in patients with cholangiocarcinoma: results from a clinical trial/in depth correlative studies and mouse studies

杜瓦卢马布 医学 贝伐单抗 内科学 彭布罗利珠单抗 癌症 免疫系统 肿瘤科 胃肠病学 免疫疗法 免疫学 化疗
作者
Mohamed-Reda Benmebarek,Tim F. Greten,Cecilia Monge,Benjamin Ruf,Yuta Myojin,Cihan Oguz,Justin Lack,William G. Telford,Changqing Xie,Tim F. Greten
出处
期刊: 卷期号:: A441-A441 被引量:2
标识
DOI:10.1136/jitc-2022-sitc2022.0419
摘要

Background

The addition of durvalumab (anti-PD-L1) to chemotherapy with gemcitabine and cisplatin has become standard of care for patients with cholangiocarcinoma. Both anti-CTLA4/anti-PD-L1 and anti-VEGF/anti-PDL1 are FDA approved immune checkpoint inhibitor regimens. Here we tested the combination of anti-CTLA4 + anti-VEGF + anti-PD-L1 in patients with cholangiocarcinoma (CCA).

Methods

In this open-label phase II study patients with histologically confirmed HCC and CCA were treated with 300 mg tremelimumab, 7.5 mg/kg bevacizumab and 1150 mg durvalumab on day 1 followed by 7.5 mg/kg bevacizumab and 1150 mg durvalumab every 3 weeks. Primary objective was the 6-month progression-free survival (PFS). Secondary endpoints include safety and correlative studies including single cell RNA-sequence analysis of PBMC, spectral flow cytometry analysis using a 22-color pan-immunological panel and a 25-color T cell-specific panel and multiplex serum cytokine analysis as well as bulk mRNA analysis from paired tumor biopsies. Immune and tumor responses were tested in mice with subcutaneously injected SB1 cholangiocarcinoma cells after treatment with anti-VEGF/anti-CTLA4 and anti-PD-L1.

Results

A total of 7 patients (6 CCA and 1 HCC) were enrolled into this study before the study was halted for unexpected high rates of immune related AEs. 4/7 patients developed grade 3 AEs including 2 patients with myositis, 1 patient with colitis, 1 patient with hepatitis, 2 patients with thyroiditis and 1 patient who developed a myocarditis, myositis, myasthenia gravis and immune thrombocytopenia. Here we present the unexpected clinical responses in CCA with 2/6 CCA patients demonstrating long-lasting partial responses (10.3 and 3.5 months) and a median OS of 13.6 months despite early treatment discontinuation. Analysis of immune correlates are ongoing. Preliminary spectral flow cytometry results demonstrated a significantly higher frequency of regulatory T cells (Tregs), proliferating CD4+ and CD8+ T cells, as well as non-classical monocytes following anti-VEGF/anti-CTLA4/anti-PD-L1 treatment. Within the CD8 T cell compartment, a CD39+Ki67+PD-1hi fraction expanded in the anti-VEGF/anti-CTLA4/anti-PD-L1 treated cohort. 10x single cell sequencing analysis confirmed the findings of the flow cytometric analysis and revealed expanded TCR clonotypes in the treated cohort. In murine studies anti-VEGF, anti-CTLA-4 and anti-PD-L1 combination resulted in marked tumor control in tumor-bearing mice mimicking results we obtained in patients with CCA.

Conclusions

Here, we show that combined anti-VEGF, anti-CTLA4 and anti-PD-L1 induces exceptional immunological and therapeutic responses in patients with cholangiocarcinoma. The study is continuing to enroll with a modified dosing schedule. Murine studies will help better to further elucidate the immunological mechanism.

Trial Registration

NCT03937830

Ethics Approval

This study has been approved by the NIH review board (#NCI-19-C-0094)

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沦落而发布了新的文献求助10
刚刚
耍酷大山发布了新的文献求助10
刚刚
耍酷大山发布了新的文献求助10
刚刚
耍酷大山发布了新的文献求助10
1秒前
耍酷大山发布了新的文献求助30
1秒前
1秒前
czh给czh的求助进行了留言
2秒前
小柴胡发布了新的文献求助10
2秒前
3秒前
耍酷大山发布了新的文献求助10
3秒前
耍酷大山发布了新的文献求助10
3秒前
4秒前
耍酷大山发布了新的文献求助10
4秒前
耍酷大山发布了新的文献求助10
5秒前
耍酷大山发布了新的文献求助10
6秒前
耍酷大山发布了新的文献求助10
6秒前
耍酷大山发布了新的文献求助10
6秒前
6秒前
耍酷大山发布了新的文献求助10
6秒前
7秒前
耍酷大山发布了新的文献求助10
7秒前
小二郎的应助被土豆采纳,获得10
8秒前
8秒前
科研通AI6.4的应助被养咩咩采纳,获得10
9秒前
科研通AI2S的应助被云隐采纳,获得10
9秒前
9秒前
胖达完成签到,获得积分10
10秒前
耍酷大山发布了新的文献求助10
10秒前
耍酷大山发布了新的文献求助10
10秒前
10秒前
耍酷大山发布了新的文献求助10
10秒前
耍酷大山发布了新的文献求助10
10秒前
耍酷大山发布了新的文献求助10
10秒前
耍酷大山发布了新的文献求助10
11秒前
耍酷大山发布了新的文献求助10
11秒前
耍酷大山发布了新的文献求助10
11秒前
大模型的应助被komorebi采纳,获得10
11秒前
石永怡完成签到,获得积分10
11秒前
科研通AI6.4的应助被呵呵采纳,获得10
11秒前
Hello的应助被唐僧洗发用飘柔采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194415
求助须知:如何正确求助?哪些是违规求助? 9580155
关于积分的说明 21870088
捐赠科研通 7793967
什么是DOI,文献DOI怎么找? 3437647
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484376